Carnation Therapeutics

Executive Summary

Carnation Therapeutics is a preclinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts. The company specializes in developing novel antisense oligonucleotide (ASO) therapies for oncology, with initial focus on lung cancer and melanoma. Its mission is to leverage cutting-edge science to improve patient care by targeting cancer at the genetic level. While still in early development, Carnation's ASO platform has the potential to address undruggable targets and overcome resistance mechanisms common in solid tumors. The company operates in a competitive landscape but differentiates itself through a proprietary approach to ASO design and delivery. As a private, pre-revenue entity, Carnation's near-term value hinges on advancing its lead candidate toward clinical trials, securing funding, and generating preclinical proof-of-concept data. Key risks include the technical challenges of ASO therapeutics and the need for capital to support IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026IND-enabling studies completion and potential IND filing40% success
• Q2 2026Presentation of preclinical efficacy data at major oncology conference60% success
• Q3 2026Series A financing announcement50% success